September 30, 2016 11:23 AM EDT

Threshold blasted, restructures after a PhII failure; SQZ raises $16M

John Carroll

Editor & Founder

South San Francisco-based Threshold Pharmaceuticals $THLD says that its mid-stage trials for its cancer drug tarloxotinib proved to be a bust, and it’s now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Threshold blasted, restructures after a PhII failure; SQZ raises $16M

John Carroll

Editor & Founder

Sign up to read this article for free.

Biosecure compromise could add executive review process for named companies, sources say

After UnitedHealthcare CEO killing, healthcare industry faces a new security reality

Eliav Barr defends Merck's LaNova deal, but cautions VEGF bispecifics have yet to deliver mature data

Lilly continues to expand its empire of GLP-1 factories with new $3B buildout

GSK's third new pact of the week focuses on Alzheimer's with startup Muna Therapeutics

FDA spells out new expedited withdrawal procedures for accelerated approvals

Thresh­old blast­ed, re­struc­tures af­ter a PhII fail­ure; SQZ rais­es $16M

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Biose­cure com­pro­mise could add ex­ec­u­tive re­view process for named com­pa­nies, sources say

Af­ter Unit­ed­Health­care CEO killing, health­care in­dus­try faces a new se­cu­ri­ty re­al­i­ty

Eli­av Barr de­fends Mer­ck­'s LaNo­va deal, but cau­tions VEGF bis­pecifics have yet to de­liv­er ma­ture da­ta

Lil­ly con­tin­ues to ex­pand its em­pire of GLP-1 fac­to­ries with new $3B build­out

GSK's third new pact of the week fo­cus­es on Alzheimer's with start­up Mu­na Ther­a­peu­tics

FDA spells out new ex­pe­dit­ed with­draw­al pro­ce­dures for ac­cel­er­at­ed ap­provals

Threshold blasted, restructures after a PhII failure; SQZ raises $16M

Biosecure compromise could add executive review process for named companies, sources say

After UnitedHealthcare CEO killing, healthcare industry faces a new security reality

Eliav Barr defends Merck's LaNova deal, but cautions VEGF bispecifics have yet to deliver mature data

Lilly continues to expand its empire of GLP-1 factories with new $3B buildout

GSK's third new pact of the week focuses on Alzheimer's with startup Muna Therapeutics

FDA spells out new expedited withdrawal procedures for accelerated approvals